Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Update

Posted by Phillip Gast on Mar 30th, 2025

Aspira Women’s Health Inc. (NASDAQ:AWH – Get Free Report) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 971,900 shares, a decrease of 35.6% from the February 28th total of 1,510,000 shares. Based on an average daily volume of 4,090,000 shares, the short-interest ratio is currently 0.2 days. Approximately 7.7% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Aspira Women’s Health in a research report on Sunday, January 12th. They issued a “hold” rating on the stock.

Read Our Latest Research Report on AWH

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. lifted its position in Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) by 33.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 316,294 shares of the company’s stock after buying an additional 79,898 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $256,000 as of its most recent filing with the SEC. 12.19% of the stock is currently owned by institutional investors and hedge funds.

Aspira Women’s Health Stock Down 4.4 %

NASDAQ:AWH opened at $0.11 on Friday. Aspira Women’s Health has a 52-week low of $0.08 and a 52-week high of $3.63. The firm has a market cap of $1.86 million, a P/E ratio of -0.09 and a beta of 1.57. The business’s 50-day moving average price is $0.25 and its 200 day moving average price is $0.60.

Aspira Women’s Health (NASDAQ:AWH – Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.13. The company had revenue of $2.35 million for the quarter, compared to analyst estimates of $3.00 million.

About Aspira Women’s Health

(Get Free Report)

Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.